

IPSEN

H1 2023 RESULTS HIGHLIGHTS

FOCUS. TOGETHER.
FOR PATIENTS & SOCIETY.


The successful delivery on our strategic roadmap is yielding more top-line growth, advancements in the pipeline and further positive developments from external innovation.

We look forward to more milestones and further expansion of the pipeline over time through additional external-innovation transactions.

I am confident, as we continue to deliver more medicines to patients, in ensuring the sustainable growth of Ipsen.

David Loew
CEO

H1 2023 TOTAL SALES



■ Oncology
■ Rare Disease
■ Neuroscience

FY 2023 GUIDANCE UPGRADE

Total-sales growth
greater than 6.0%
(at constant exchange rates)

Core operating margin
greater than 30.0% of total sales

KEY FINANCIALS

Core operating income
€523m | **-7.9%**

Free cash flow
€371m | **+9.6%**


Core operating margin
34.0% | **-5.6%pts**

Core earnings per share¹
€4.73 | **-6.6%**

GEOGRAPHIC BREAKDOWN

H1 2023 TOTAL SALES BY REGION

32% North America | **40%** Europe | **28%** Rest of World



PIPELINE UPDATE

Onivyde: sNDA accepted (U.S.) in first-line metastatic pancreatic ductal adenocarcinoma

Bylvay: regulatory approval (U.S.): Alagille syndrome

Palovarotene: favorable outcome from U.S. Advisory Committee² meeting (FOP)

Elafibranor: positive top-line data from pivotal ELATIVE Phase III trial

Total-sales growth is at constant exchange rates; all other growth rates are at actual exchange rates.
¹ Fully diluted. ²The U.S. FDA Endocrinologic and Metabolic Drugs Advisory Committee.
sNDA: supplemental New Drug Application; FOP: fibrodysplasia ossificans progressiva.

For further information on Ipsen's H1 2023 results and definitions of financial indicators, please refer to the press release at:

www.ipsen.com/investors

Craig Marks

Vice President, Investor Relations
+44 7584 349 193
craig.marks@ipsen.com

Nicolas Bogler

Senior Manager, Investor Relations
+33 6 52 19 98 92
nicolas.bogler@ipsen.com

IPSEN
Innovation for patient care